Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BPTF | Q12830 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337198 | 0.75 | ACHE (0.48) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL19475249 | 0.71 | ACHE (0.44) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL18007707 | 0.71 | ACHE (0.44) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL18007560 | 0.71 | ACHE (0.44) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL18007601 | 0.71 | ACHE (0.44) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL25198544 | 0.69 | ACHE (0.42) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL25198553 | 0.69 | ACHE (0.42) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL5404192 | 0.66 | CYP3A4 (0.37) | ACHEMAPK1 | |
| SCHEMBL25236247 | 0.65 | ACHE (0.39) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL19474937 | 0.65 | ALDH1A1 (0.47) | ACHEMEN1MAPK1KMT2ABPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010772-A1 | NLRP3 INHIBITORS | KODIAK SCIENCES INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20220267276-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2022-08-25 | — | — | US | disclosed |
| EP-3880659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-3817817-A1 | NLRP MODULATORS | Novartis AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ACHE 4294/4885MEN1 3277/4885MAPK1 1462/4885 |
| US-20220267276-A1 | NLRP MODULATORS | NLRP1, NRP1, NR4A3 | ACHE 4882/4885MEN1 4566/4885MAPK1 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.